Novartis said its RNA therapy del-brax met goals of a Phase 1/2 study in facioscapulohumeral muscular dystrophy (FSHD), an inherited muscle disorder that currently has no FDA-approved medicines. Del-brax is one of three RNA therapies from Novartis’s $12 billion acquisition of Avidity Biosciences. The post Novartis RNA Med From $12B Deal Keeps Building Case to…
The next phase of AI in healthcare is about building systems where human clinicians, supervisors, and AI can all contribute, challenge each other, and improve how decisions are made. The post From Copilots to Clinical Judgment: The Next Phase of AI in Digital Behavioral Health appeared first on MedCity News.
AI is not driving healthcare cost inflation. It is exposing a system that has always been designed to reward it, and making that system more efficient. As long as reimbursement is tied to intensity, every technological advancement will move in the same direction: toward maximizing it. The post AI Is Scaling Healthcare Costs Because the…
EHR switching involves risk. But taking a life cycle view, considering data migration, workflow configuration, training, downtime, ongoing fees and eventual exit terms, can put an end to your EHR pain. The post What Healthcare Leaders Get Wrong About EHR Switching appeared first on MedCity News.
[Sponsored] A webinar sponsored by Verato and scheduled for June 17 from 1 pm to 2 pm ET will explore how a unified identity strategy, spanning patients, providers, and emerging solutions enabling accurate attribution, strengthens interoperability, and ultimately drives VBC success. Register today! The post The Identity Gap Undermining Value-Based Care appeared first on MedCity News.
The Digital Medicine Society launched an initiative to help payers and virtual care providers avoid common contract implementation challenges. The post DiMe Launches New Initiative for Virtual-First Care appeared first on MedCity News.
During a panel at HFMA’s annual conference, two healthcare credit analysts said the industry is already fracturing into winners and losers. And with 2030 bringing a perfect storm of demographic pressure, reimbursement cuts and AI disruption, they think window for bold action is closing fast. The post ‘2030 Scares Me to Death’: Credit Analysts’ Urgent…
Parabilis Medicines is developing a new type of peptide drug capable of hitting elusive disease targets inside cells. Cancer is the biotech’s initial focus, and the IPO cash will support a lead program zolucatetide, which is in development for a rare type of tumor with limited treatment options. The post Parabilis Medicines’ Quest to Drug…
The next evolution of patient experience will not be defined by more digital touchpoints. It will be defined by giving nurses and care teams the capacity to be fully present. The post Restoring the Patient-Clinician Relationship to the Center of Care appeared first on MedCity News.
Prevention requires more than faster detection. Organizations need payment programs with end-to-end visibility and controls that intervene before losses occur. The post From Detection to Defense: Building Fraud-Resilient Healthcare Payment Systems appeared first on MedCity News.